Compounds > taccalonolide e

Page last updated: 2024-11-13

taccalonolide e

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

taccalonolide E: has microtubule-stabilizing activity; isolated from Tacca chantrieri; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	56672430
CHEMBL ID	1821840
SCHEMBL ID	16273055
MeSH ID	M0452060

Synonyms (3)

Synonym
taccalonolide e
CHEMBL1821840
SCHEMBL16273055

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay ID	Title	Year	Journal	Article
AID617741	Toxicity in B6C3F1 mouse allografted with mouse 16/C cells assessed as mean body weight loss at 54 mg/kg, iv administered on days 1,4,6, 8, 9, 10 and 11 (Rvb = -2.2%)	2011	Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17	Identification and biological activities of new taccalonolide microtubule stabilizers.
AID617645	Antitumor activity against mouse 16/C cells allografted in mouse B6C3F1 assessed as decrease in tumor mass at 90 mg/kg, iv administered on days 1,4,6, 8, 9, 10 and 11 relative to control	2011	Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17	Identification and biological activities of new taccalonolide microtubule stabilizers.
AID617743	Toxicity in B6C3F1 mouse allografted with mouse 16/C cells assessed as lethality at 54 mg/kg, iv administered on days 1,4,6, 8, 9, 10 and 11 measured after 12 days relative to control	2011	Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17	Identification and biological activities of new taccalonolide microtubule stabilizers.
AID617548	Induction of interphase microtubule bundling in human HeLa cells at 2.5 uM after 18 hrs by indirect immunofluorescence analysis	2011	Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17	Identification and biological activities of new taccalonolide microtubule stabilizers.
AID617635	Cell cycle arrest in human HeLa cells assessed as accumulation of cells at G2/M phase at 2.5 uM after 18 hrs by flow cytometric analysis	2011	Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17	Identification and biological activities of new taccalonolide microtubule stabilizers.
AID617734	Antitumor activity against mouse 16/C cells allografted in mouse B6C3F1 assessed as gross log cell killing at 54 mg/kg, iv administered on days 1,4,6, 8, 9, 10 and 11 relative to control	2011	Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17	Identification and biological activities of new taccalonolide microtubule stabilizers.
AID617742	Toxicity in B6C3F1 mouse allografted with mouse 16/C cells assessed as lethality at 90 mg/kg, iv administered on days 1,4,6, 8, 9, 10 and 11 measured after 12 days relative to control	2011	Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17	Identification and biological activities of new taccalonolide microtubule stabilizers.
AID762819	Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay	2013	Journal of natural products, Jul-26, Volume: 76, Issue:7	Hydrolysis reactions of the taccalonolides reveal structure-activity relationships.
AID617733	Antitumor activity against mouse 16/C cells allografted in mouse B6C3F1 assessed as gross log cell killing at 90 mg/kg, iv administered on days 1,4,6, 8, 9, 10 and 11 relative to control	2011	Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17	Identification and biological activities of new taccalonolide microtubule stabilizers.
AID617740	Toxicity in B6C3F1 mouse allografted with mouse 16/C cells assessed as mean body weight loss at 90 mg/kg, iv administered on days 1,4,6, 8, 9, 10 and 11 (Rvb = -2.2%)	2011	Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17	Identification and biological activities of new taccalonolide microtubule stabilizers.
AID617726	Antitumor activity against mouse 16/C cells allografted in mouse B6C3F1 assessed as delay in tumor growth at 90 mg/kg, iv administered on days 1,4,6, 8, 9, 10 and 11 relative to control	2011	Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17	Identification and biological activities of new taccalonolide microtubule stabilizers.
AID1180503	Antiproliferative activity against human HeLa cells by SRB assay	2014	Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14	Synthetic reactions with rare taccalonolides reveal the value of C-22,23 epoxidation for microtubule stabilizing potency.
AID617727	Antitumor activity against mouse 16/C cells allografted in mouse B6C3F1 assessed as delay in tumor growth at 54 mg/kg, iv administered on days 1,4,6, 8, 9, 10 and 11 relative to control	2011	Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17	Identification and biological activities of new taccalonolide microtubule stabilizers.
AID616233	Inhibition of beta tubulin in human HeLa cells assessed asultiple abnormal mitotic spindle formation at 2.5 uM after 18 hrs by immunofluorescence analysis	2011	Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17	Identification and biological activities of new taccalonolide microtubule stabilizers.
AID617646	Antitumor activity against mouse 16/C cells allografted in mouse B6C3F1 assessed as decrease in tumor mass at 54 mg/kg, iv administered on days 1,4,6, 8, 9, 10 and 11 relative to control	2011	Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17	Identification and biological activities of new taccalonolide microtubule stabilizers.
AID617639	Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay	2011	Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17	Identification and biological activities of new taccalonolide microtubule stabilizers.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (28.57)	29.6817
2010's	5 (71.43)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.51 (24.57)
Research Supply Index	2.08 (2.92)
Research Growth Index	4.59 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.51)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (14.29%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (85.71%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.48	2	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
taccalonolide a taccalonolide A: has microtubule stabilizing activity; isolated from Tacca chantrieri; structure in first source	4.4	6	0	withanolide
taccalonolide aj taccalonolide AJ: isolated from plants of the genus Tacca; structure in first source	2.49	2	0

Condition	Indicated	Relationship Strength	Studies	Trials
Experimental Mammary Neoplasms [description not available]	0	2.06	1	0
Experimental Neoplasms [description not available]	0	2.1	1	0
Breast Cancer [description not available]	0	2.44	2	0
Carcinoma, Epidermoid [description not available]	0	2.06	1	0
Cancer of Mouth [description not available]	0	2.06	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	0	2.44	2	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	0	2.06	1	0
Mouth Neoplasms Tumors or cancer of the MOUTH.	0	2.06	1	0
Cancer of Ovary [description not available]	0	2.01	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	0	2.01	1	0